Hatice Mine Cakmak

Dr. Hatice Mine Cakmak

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Pediatrics & Neonatology
Verified
Journal Article
Open access
HCHatice Mine Cakmak
Hatice Mine Cakmak
OKOmer Kartal
Omer Kartal
AKAYCA KOCAAGA
AYCA KOCAAGA
YBYasar Bildirici
Yasar Bildirici
Unlike in adults, there is no consensus on management and diagnosis of polycythemia in children. This study aims to evaluate the diagnosis and verify the algorithm in children with polycythemia. Seventy-nine children with polycythemia were followed-up in our pediatric hematology-oncology clinic between December 15, 2019, and July 15, 2021. After eliminating secondary causes (hypoxia, pulmonary, cardiac diseases), we checked for genetic mutations, including congenital erythrocytosis gene panel (JAK, EPOR, EPAS1, EGNL1, HBB, HBA, BPGM, and VHL). We also compared parameters for secondary and idiopathic polycythemia groups. Of the 79 children, thirty-five had secondary polycythemia (hypoxia, pulmonary, cardiac diseases), and one was diagnosed with a novel likely pathogenic mutation c.2089C > G; p.Pro697Ala in exon 13 of EPAS1 gene. Others (n = 35) had persistent and idiopathic polycythemia. Here, we compared the idiopathic and secondary cases. We found that the ratio of family history of polycythemia (n = 4 (9.5%) vs 0%, respectively) was higher in the second group (p = 0.009). In addition, the mean age (14.7 ± 3.52 vs 13.4 ± 4.67 respectively) (p = 0.042) and the ratio of erythroid hyperplasia in bone marrow [n = 3 (8.6%) vs 0% respectively] (p = 0.003) was higher in the idiopathic polycythemia group, compared to secondary polycythemia patients. Finding the genetic defect in polycythemia is a significant issue. Due to being a rarity in children, the first line JAK mutation analysis should be performed in selected cases. This study is the first description of a Turkish patient with EPAS1 p.Pro697Ala mutation, thereby expanding our knowledge about the clinical features of the disease. However, new investigations are required to confirm its function.

1 March 2020 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
NTNurdan Taçyıldız
Nurdan Taçyıldız
EUEmel Unal
Emel Unal
HDHandan Dinçaslan
Handan Dinçaslan
HCHatice Mine Cakmak
Hatice Mine Cakmak
KKKenan Köse
Kenan Köse
ÖKÖmer Kartal
Ömer Kartal
Background: The immunomodulator mifamurtide plus a chemotherapy regimen has been shown to significantly improve the outcome in non-metastatic osteosarcoma patients. We report the results of the addition of mifamurtide to chemotherapy in newly diagnosed patients with osteosarcoma. Methods: A total of 36 children with osteosarcoma without detectable metastasis were treated between November 2010 and April 2018 at the Ankara University Department of Pediatric Oncology. Mifamurtide was added to the chemotherapy regimen in 17 patients while the remaining 19 did not receive mifamurtide. The probabilities of metastasis and overall survival were compared between the groups. Results: The 43-month survival rate was 87.5% and 89.9% in the patients who received and did not receive mifamurtide, respectively (p=0.65). Common side effects of mifamurtide were chills and fever. The addition of mifamurtide in the high-risk group with ≤95% necrosis tended to decrease the probability of distant metastasis (36.4% vs. 58.3%) (p=0.39). The time to metastasis in the group with positive surgical margins (4 months in one patient in the non-mifamurtide group, 7 and 20 months in the mifamurtide group) was also longer in the mifamurtide group. During the 43-month follow up period, median time to metastasis was longer in the mifamurtide group (20 vs. 5 months). In addition, mifamurtide plus chemotherapy decreased the risk of metastasis in the cases with primary site relapse. Conclusions: The addition of mifamurtide to chemotherapy might improve event-free survival by decreasing the probability of distant metastasis in bad histologic responders, and also by increasing the time to distant metastasis in the surgical margin positive group. Additional clinical studies are necessary to determine the long-term effects of mifamurtide on metastatic disease.

1 May 2021
Verified
Journal Article
Closed access
NTNurdan Tacyildiz
Nurdan Tacyildiz
HCHatice Mine Cakmak
Hatice Mine Cakmak
EUEmel Unal
Emel Unal
HDHandan Dincaslan
Handan Dincaslan
GTGulsah Tanyildiz
Gulsah Tanyildiz
GYGulsan Yavuz
Gulsan Yavuz

9 January 2024 in Indian Journal of Cancer
Verified
Journal Article
Open access
NTNurdan Tacyildiz
Nurdan Tacyildiz
HCHatice Mine Cakmak
Hatice Mine Cakmak
EUEmel Unal
Emel Unal
HDHandan Dincaslan
Handan Dincaslan
HTHikmet Gülşah Tanyıldız
Hikmet Gülşah Tanyıldız
IKIşınsu Kuzu
Işınsu Kuzu
Background: Long-term survivors of Hodgkin lymphoma (HL) are at risk of developing a range of late effects, with a second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The present study aims to evaluate the late side effects in children with HL. Materials and Methods: Out of 53 HL patients, we assessed the long-term effects of childhood HL survivors (HLSs; n = 50) diagnosed between 1998 and 2019. Patient data related to chronic health conditions, and sociodemographic characteristics were compared with their siblings ( n = 56). Results: The cumulative overall survival (OS) at 1, 5, and 10 years from diagnosis was 98.1 ± 1.9%, 93.3 ± 3.8%, and 93.3 ± 3.8%, respectively. Groups of HLSs and their siblings were matched according to age and gender. Compared with siblings, survivors had will be changed as ‘a higher frequency of nephrotoxicity ( P = 0.02)’, cardiotoxicity ( P = 0.12), thyroid dysfunction ( P = 0.001), health care service usage ( P < 0.01), limitation of physical function ( P = 0.01), and pulmonary disease ( P = 0.01). The control group of siblings had a higher incidence of marital status ( P < 0.01), parenthood ( P = 0.01), and smoking habit ( P = 0.03). Thyroid dysfunction was associated with neck radiotherapy ( P < 0.01). No secondary neoplasm was detected. In relapsed, refractory setting ( n = 10), autologous transplantation ( n = 9) is performed after a complete remission. Brentuximab vedotin with or without bendamustine and rituximab is also used in selected patients. Conclusions: Increased number of chronic health conditions and social problems point to the significance of long-term follow-up of HLSs. We are currently preparing a survivorship guideline appropriate for Turkey’s conditions. Implications for Cancer Survivors: Renal, heart, pulmonary impairment, thyroid dysfunction, limitation in physical functioning, and deterioration in social status (marriage, having children, education).

30 April 2023 in Interdisciplinary Medical Journal
Verified
Journal Article
Open access
PDF file
HCHatice Mine Cakmak
Hatice Mine Cakmak
KKKenan Kocabay
Kenan Kocabay
Objective: In previous studies, chronicity risk factors for idiopathic thrombocytopenic purpura (ITP) are unclear. This study aimed to evaluate the outcome of children with ITP and determine the chronicity risk factors. Methods: This study retrospectively examined the demographics, laboratories, outcome, and chronicity risk factors among sixty children with ITP and obtained the data from the computer system. We analyzed demographics, treatment, and laboratory risk factors for chronic ITP by IBM SPSS and used binary logistic regression analysis. Results: Of 60 children with ITP, 32 (53.3%) had acute, 25 (41.7%) had chronic, and 3 (5%) had persistent ITP. Demographics, laboratories (age <4 years, thrombocyte count at diagnosis, serum LDH, neutrophil count, mean platelet volume, status and grade of bleeding, infection in the last month) were unrelated to chronic ITP. As a new finding, loss of treatment response rates predicts chronicity in both univariate OR [2.56 (1.25 – 5.25)](p=0.01) and multivariate analysis OR [3.873 (1.488–10.08](p=0.006). Among second-line therapies, eltrombopag (n=6) achieved a durable response of thrombocyte count for more than 50.000/mm³ in five. However, two required the cessation of treatment two due to renal failure. Of two splenectomized patients, one could not achieve remission. Conclusion: Lower platelet counts (<20.000/mm³), younger age, male gender, and initial treatment regimens (IVIG, steroid, IVIG plus steroid) did not influence chronicity in our study. We suggest that loss of response rates predicts chronicity as a new factor.

26 June 2024 in Child: Care, Health and Development
Verified
Journal Article
Closed access
HCHatice Mine Cakmak
Hatice Mine Cakmak
KKKenan Kocabay
Kenan Kocabay
RTRamazan Cahit Temizkan
Ramazan Cahit Temizkan
STSevim Turay
Sevim Turay
SOSukriye Ozde
Sukriye Ozde
ECEmel Coşkun
Emel Coşkun